ArticleCancer gene therapy2007
Engineered herpes simplex virus expressing bacterial cytosine deaminase for experimental therapy of brain tumors.
Article in Cancer gene therapy, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 39 citations in OpenAlex.
- Bioreductive prodrug PR-104 improves the tumour distribution and titre of the nitroreductase-armed oncolytic adenovirus ONYX-411Cancer gene therapy · 2022Article
- Progress of oncolytic virotherapy for neuroblastoma.Frontiers in pediatrics · 2022Review
- Immunovirotherapy for the Treatment of Glioblastoma and Other Malignant Gliomas.Neurosurgery clinics of North America · 2021Review
- Oncolytic Viruses for Cancer Therapy: Barriers and Recent Advances.Molecular therapy oncolytics · 2019Review
- Role of Herpes Simplex Virus 1 γ34.5 in the Regulation of IRF3 Signaling.Journal of virology · 2017Article
- Preclinical Mouse Models for Analysis of the Therapeutic Potential of Engineered Oncolytic Herpes Viruses.ILAR journal · 2016Review
- Enhanced EJ Cell Killing of (125)I Radiation by Combining with Cytosine Deaminase Gene Therapy Regulated by Synthetic Radio-Responsive Promoter.Cancer biotherapy & radiopharmaceuticals · 2015Article
- Evaluation of the safety and biodistribution of M032, an attenuated herpes simplex virus type 1 expressing hIL-12, after intracerebral administration to aotus nonhuman primates.Human gene therapy. Clinical development · 2014Article
- Current status of gene therapy for breast cancer: progress and challenges.The application of clinical genetics · 2014Review
- Construction and Characterization of Recombinant HSV-1 Expressing Early Growth Response-1.ISRN virology · 2014Article
- Combinatorial strategies for oncolytic herpes simplex virus therapy of brain tumors.CNS oncology · 2013Review
- Preclinical evaluation of engineered oncolytic herpes simplex virus for the treatment of neuroblastoma.PloS one · 2013Article
- Bugs and drugs: oncolytic virotherapy in combination with chemotherapy.Current pharmaceutical biotechnology · 2012Review
- Oncolytic herpes simplex virus expressing yeast cytosine deaminase: relationship between viral replication, transgene expression, prodrug bioactivation.Cancer gene therapy · 2012Article
- Strategies for the rapid construction of conditionally-replicating HSV-1 vectors expressing foreign genes as anticancer therapeutic agents.Molecular pharmaceutics · 2011Review
- Oncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer?Future oncology (London, England) · 2010Review
- Oncolysis using herpes simplex virus type 1 engineered to express cytosine deaminase and a fusogenic glycoprotein for head and neck squamous cell carcinoma.Archives of otolaryngology--head & neck surgery · 2010Article
- Intelligent design: combination therapy with oncolytic viruses.Molecular therapy : the journal of the American Society of Gene Therapy · 2010Review
- Herpes simplex virus oncolytic therapy for pediatric malignancies.Molecular therapy : the journal of the American Society of Gene Therapy · 2009Review
- Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors.Cancer research · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Lack of effective therapy of primary brain tumors has promoted the development of novel experimental approaches utilizing oncolytic viruses combined with gene therapy. Towards this end, we have assessed a conditionally replication-competent, gamma(1)34.5-deleted herpes simplex virus type 1 (HSV-1) expressing cytosine deaminase (CD) for treatment of malignant brain tumors. Our results are summarized as follows: (i) a recombinant HSV (M012) was constructed in which both copies of the gamma(1)34.5 gene were replaced with the bacterial CD gene, under the control of the cellular promoter Egr-1; (ii) M012-infected cells in vitro efficiently convert 5-fluorocytosine (5-FC) to 5-fluorouracil, thereby enhancing cytotoxicity of neighboring, uninfected cells; (iii) both direct and bystander cytotoxicity of murine neuroblastoma and human glioma cell lines after infection with M012 were demonstrated; (iv) direct intracerebral inoculation of A/J mice demonstrated lack of neurotoxicity at doses similar to G207, a gamma(1)34.5-deleted HSV with demonstrated safety in human patient trials and (v) intratumoral injection of M012 into Neuro-2a flank tumors in combination with 5-FC administration significantly reduced tumor growth versus tumors treated with R3659 combined with 5-FC, or treated with M012 alone. Thus, M012 is a promising new oncolytic HSV vector with an enhanced prodrug-mediated, antineoplastic effect that is safe for intracranial administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.